Will Pfizer's (PFE) New Drugs Provide a Boost to 2024 Sales?
Pfizer(US:PFE) Zacks Investment Research·2024-04-11 14:16Pfizer (PFE) has been relying on its newly launched and newly acquired products to improve its sales performance amid a decline in revenues from its COVID-19 products.Pfizer records direct sales and alliance revenues from its partner, BioNTech (BNTX) , for the COVID-19 vaccine, Comirnaty, and product revenues from its oral antiviral pill for COVID, Paxlovid. However, revenues from its COVID products are declining due to a demand slump.Nonetheless, Pfizer expects better non-COVID operational revenue growth i ...